209 related articles for article (PubMed ID: 32352655)
1. Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response.
Miller S; Stewart ID; Clements D; Soomro I; Babaei-Jadidi R; Johnson SR
J Pathol Clin Res; 2020 Jul; 6(3):215-226. PubMed ID: 32352655
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin K in Lymphangioleiomyomatosis: LAM Cell-Fibroblast Interactions Enhance Protease Activity by Extracellular Acidification.
Dongre A; Clements D; Fisher AJ; Johnson SR
Am J Pathol; 2017 Aug; 187(8):1750-1762. PubMed ID: 28623674
[TBL] [Abstract][Full Text] [Related]
3. Mast-Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis.
Babaei-Jadidi R; Dongre A; Miller S; Castellanos Uribe M; Stewart ID; Thompson ZM; Nateri AS; Bradding P; May ST; Clements D; Johnson SR
Am J Respir Crit Care Med; 2021 Aug; 204(4):431-444. PubMed ID: 33882264
[No Abstract] [Full Text] [Related]
4. Cathepsin K is Superior to HMB45 for the Diagnosis of Pulmonary Lymphangioleiomyomatosis.
Rolim I; Makupson M; Lovrenski A; Farver C
Appl Immunohistochem Mol Morphol; 2022 Feb; 30(2):108-112. PubMed ID: 34433182
[TBL] [Abstract][Full Text] [Related]
5. Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.
Kristof AS; You Z; Han YS; Giaid A
Peptides; 2010 Aug; 31(8):1511-6. PubMed ID: 20433884
[TBL] [Abstract][Full Text] [Related]
6. Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
Nascimento ECTD; Baldi BG; Mariani AW; Annoni R; Kairalla RA; Pimenta SP; da Silva LFF; Carvalho CRR; Dolhnikoff M
Respir Res; 2018 May; 19(1):83. PubMed ID: 29739412
[TBL] [Abstract][Full Text] [Related]
7. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
Hayashi T; Kumasaka T; Mitani K; Okada Y; Kondo T; Date H; Chen F; Oto T; Miyoshi S; Shiraishi T; Iwasaki A; Hara K; Saito T; Ando K; Kobayashi E; Gunji-Niitsu Y; Kunogi M; Takahashi K; Yao T; Seyama K
Hum Pathol; 2016 Apr; 50():34-42. PubMed ID: 26997436
[TBL] [Abstract][Full Text] [Related]
8. Effect of beta-agonists on LAM progression and treatment.
Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
[TBL] [Abstract][Full Text] [Related]
9. Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
Krymskaya VP; McCormack FX
Annu Rev Med; 2017 Jan; 68():69-83. PubMed ID: 28099079
[TBL] [Abstract][Full Text] [Related]
10. Angiomyomatous hamartoma of lymph nodes, revisited: clinicopathologic study of 21 cases, emphasizing its distinction from lymphangioleiomyomatosis of lymph nodes.
Moh M; Sangoi AR; Rabban JT
Hum Pathol; 2017 Oct; 68():175-183. PubMed ID: 28899738
[TBL] [Abstract][Full Text] [Related]
11. Intracrine steroid production and mammalian target of rapamycin pathways in pulmonary lymphangioleiomyomatosis.
Adachi K; Miki Y; Saito R; Hata S; Yamauchi M; Mikami Y; Okada Y; Seyama K; Kondo T; Sasano H
Hum Pathol; 2015 Nov; 46(11):1685-93. PubMed ID: 26298231
[TBL] [Abstract][Full Text] [Related]
12. Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis.
Clements D; Dongre A; Krymskaya VP; Johnson SR
PLoS One; 2015; 10(5):e0126025. PubMed ID: 25978616
[TBL] [Abstract][Full Text] [Related]
13. In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human Lymphangioleiomyomatosis.
Krencz I; Sebestyen A; Papay J; Jeney A; Hujber Z; Burger CD; Keller CA; Khoor A
Hum Pathol; 2018 Sep; 79():199-207. PubMed ID: 29885404
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta 1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis.
Evans SE; Colby TV; Ryu JH; Limper AH
Chest; 2004 Mar; 125(3):1063-70. PubMed ID: 15006970
[TBL] [Abstract][Full Text] [Related]
15. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis.
Kumasaka T; Seyama K; Mitani K; Sato T; Souma S; Kondo T; Hayashi S; Minami M; Uekusa T; Fukuchi Y; Suda K
Am J Surg Pathol; 2004 Aug; 28(8):1007-16. PubMed ID: 15252306
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors.
Martignoni G; Pea M; Reghellin D; Gobbo S; Zamboni G; Chilosi M; Bonetti F
Arch Pathol Lab Med; 2010 Jan; 134(1):33-40. PubMed ID: 20073603
[TBL] [Abstract][Full Text] [Related]
17. Lymphangioleiomyomatosis - a wolf in sheep's clothing.
Henske EP; McCormack FX
J Clin Invest; 2012 Nov; 122(11):3807-16. PubMed ID: 23114603
[TBL] [Abstract][Full Text] [Related]
18. Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir LM
Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
[TBL] [Abstract][Full Text] [Related]
19. LAM cells biology and lymphangioleiomyomatosis.
Grzegorek I; Drozdz K; Podhorska-Okolow M; Szuba A; Dziegiel P
Folia Histochem Cytobiol; 2013; 51(1):1-10. PubMed ID: 23690211
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
